Detailed Narrative
Q3 FY26 Performance Overview and Recovery
Hikal reported consolidated revenue of INR494 crores and EBITDA of INR83 crores for Q3 FY26, translating to an EBITDA margin of 16.8%. This marks a clear return to operational profitability, supported by improved demand visibility and utilization. For the nine months ended December 31, 2025, consolidated revenue stood at INR1,193 crores with an EBITDA of INR115 crores (9.6% margin). The company anticipates a strong recovery in H2 FY26, with Q4 expected to outperform Q3.
Pharmaceutical Segment Performance and Regulatory Progress
The Pharmaceutical division delivered INR337 crores in revenue for Q3 FY26, achieving an EBIT margin of 12.3%. This performance signals a return to normalized trade cycles after previous headwinds. Remedial actions concerning the US FDA audit are progressing well, with the remediation plan submitted and an update provided on February 9. The company expects to hear back from the FDA within two weeks, and double-digit volume growth in pharma is anticipated to return next year, delayed by approximately one quarter due to the FDA impact.
Crop Protection Segment Challenges and Diversification
The Crop Protection segment recorded revenues of INR157 crores with a low EBIT margin of 3% in Q3 FY26. This segment continues to face persistent pricing pressures and structural overcapacity, particularly from China. In response, Hikal is accelerating its portfolio diversification strategy, focusing on specialty chemicals, especially the Personal Care segment. The company expects meaningful revenue from this new segment to commence in the next fiscal year, with 2 products already commercialized in Q3.
Strategic Investments and R&D Pipeline
Hikal has made strategic investments over the last 12-15 months, including a state-of-the-art high-potency laboratory and R&D centre in Pune (INR10-11 crores for Phase I) and a new pilot plant in Panoli. These facilities enhance its CDMO capabilities in high-technology segments. The R&D pipeline is robust, with 8-9 molecules in advanced stages, and the company aims for a launch velocity of 2-3 new products annually. Key starting materials for global innovators are in Phase III clinical trials, with commercial launch scheduled for FY28.
Capital Allocation and Debt Management
The Board approved an interim dividend of INR0.2 per share (10% of face value). Capital expenditure for the first nine months of FY26 stood at INR100 crores, focused on debottlenecking and capacity expansion. The full-year FY26 capex guidance has been revised downwards from INR200 crores to INR150 crores. Finance costs reduced by 17% YoY to INR48 crores, and the debt-equity ratio was maintained at 0.58 as of December 31, 2025. The company also reduced working capital by INR50 crores in 9M FY26 compared to March 2025, and anticipates overall debt reduction from FY29 onwards.
Animal Health Business Growth and Outlook
The Animal Health business continues to see sustained momentum, driven by outsourcing trends and a steady pipeline of new development projects. Hikal has a master plan to build this into an INR500 crores plus business within the next 4-5 years, with gross margins expected to be in the 45-50% range. While volumes are not yet tremendously large, they are growing, and utilization of Animal Health facilities is expected to increase in FY27 as global approvals come through for customer products.